Lytix Biopharma AS (LYTIX) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.969x

Based on the latest financial reports, Lytix Biopharma AS (LYTIX) has a cash flow conversion efficiency ratio of -0.969x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-59.85 Million ≈ $-6.30 Million USD) by net assets (Nkr61.75 Million ≈ $6.50 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Lytix Biopharma AS - Cash Flow Conversion Efficiency Trend (2017–2025)

This chart illustrates how Lytix Biopharma AS's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read LYTIX liabilities breakdown for a breakdown of total debt and financial obligations.

Lytix Biopharma AS Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Lytix Biopharma AS ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Embellence Group AB ST:EMBELL	0.080x
Agrify Corp NASDAQ:AGFY	-0.459x
AGF A/S CO:AGF-B	-0.067x
Toma as PR:TOMA	N/A
Silvercrest Asset Management Group Inc NASDAQ:SAMG	0.175x
Ardea Resources Ltd AU:ARL	-0.022x
Hun Yenilenebilir Enerji Uretim AS IS:HUNER	0.014x
Kjell Group AB ST:KJELL	0.245x

Annual Cash Flow Conversion Efficiency for Lytix Biopharma AS (2017–2025)

The table below shows the annual cash flow conversion efficiency of Lytix Biopharma AS from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see LYTIX market cap.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Nkr61.75 Million ≈ $6.50 Million	Nkr-59.85 Million ≈ $-6.30 Million	-0.969x	-48.60%
2024-12-31	Nkr107.89 Million ≈ $11.35 Million	Nkr-70.37 Million ≈ $-7.41 Million	-0.652x	+65.12%
2023-12-31	Nkr51.32 Million ≈ $5.40 Million	Nkr-95.97 Million ≈ $-10.10 Million	-1.870x	-385.00%
2022-12-31	Nkr135.13 Million ≈ $14.22 Million	Nkr-52.10 Million ≈ $-5.48 Million	-0.386x	-62.86%
2021-12-31	Nkr189.62 Million ≈ $19.95 Million	Nkr-44.90 Million ≈ $-4.72 Million	-0.237x	+80.66%
2020-12-31	Nkr19.89 Million ≈ $2.09 Million	Nkr-24.35 Million ≈ $-2.56 Million	-1.224x	+54.85%
2019-12-31	Nkr13.58 Million ≈ $1.43 Million	Nkr-36.82 Million ≈ $-3.87 Million	-2.711x	-53.27%
2018-12-31	Nkr41.05 Million ≈ $4.32 Million	Nkr-72.62 Million ≈ $-7.64 Million	-1.769x	+70.06%
2017-12-31	Nkr11.79 Million ≈ $1.24 Million	Nkr-69.67 Million ≈ $-7.33 Million	-5.909x	--

About Lytix Biopharma AS

OL:LYTIX Norway Biotechnology

Market Cap

$89.42 Million

Nkr849.75 Million NOK

Market Cap Rank

#19755 Global

#177 in Norway

Share Price

Nkr11.05

Change (1 day)

+2.31%

52-Week Range

Nkr6.90 - Nkr11.50

All Time High

Nkr18.60